Published in Curr Oncol Rep on February 01, 2012
Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol (2012) 2.05
Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res (2015) 1.12
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene (2014) 1.10
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett (2014) 0.86
Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer. Onco Targets Ther (2014) 0.77
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Successful use of bevacizumb and paclitaxel in a male breast cancer with liver metastases. Int J Clin Exp Med (2014) 0.75
A rectovaginal fistula after treatment with bevacizumab. A dangerous side effect needing emergency treatment. Clin Case Rep (2016) 0.75
A Quininib Analogue and Cysteinyl Leukotreine Receptor Antagonist inhibits VEGF-Independent Angiogenesis and Exerts an Additive Anti-angiogenic Response with Bevacizumab. J Biol Chem (2016) 0.75
Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer. Oncologist (2011) 0.75
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Clin Cancer Res (2016) 0.75
VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. Oncogene (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal (2007) 3.36
Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol (2010) 3.07
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res (2008) 2.81
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer (2006) 2.33
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 2.23
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol (2009) 2.18
Will evidence ever be sufficient to resolve the challenge of cost containment? J Clin Oncol (2011) 2.11
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol (2009) 1.97
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat (2010) 1.79
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol (2010) 1.73
Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther (2007) 1.68
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol (2009) 1.54
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol (2007) 1.23
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol (2010) 1.14
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol (2003) 1.13
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer (2009) 1.01
RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer (2008) 0.99
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study. Ann Oncol (2011) 0.89
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86
Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol (2010) 0.82
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol (2006) 1.81
Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med (2012) 1.69
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol (2012) 1.55
Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol (2004) 1.50
Metamizole use among Hispanics in Miami: report of a survey conducted in a primary care setting. South Med J (2006) 1.39
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer (2011) 1.36
Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med (2008) 1.27
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23
Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.21
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer (2009) 1.14
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14
Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer. J Thorac Oncol (2014) 1.13
Participation in cancer clinical trials: why are patients not participating? Med Decis Making (2013) 1.10
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol (2014) 1.08
Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast (2007) 1.06
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother (2007) 1.03
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat (2006) 1.02
Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res (2006) 1.02
Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer (2006) 1.01
Severe colitis associated with docetaxel use: A report of four cases. World J Gastrointest Oncol (2010) 1.01
Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat (2012) 0.95
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res (2013) 0.93
A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Clin Breast Cancer (2008) 0.92
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat (2013) 0.91
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer (2006) 0.90
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol (2011) 0.90
Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res Treat (2012) 0.90
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat (2011) 0.90
Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida. Int J Behav Med (2014) 0.89
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol (2010) 0.86
A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region. Orphanet J Rare Dis (2014) 0.86
[Validity and reliability of the Center for Epidemiologic Studies-Depression scale in Colombian adolescent students]. Biomedica (2009) 0.86
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol (2014) 0.86
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs (2013) 0.85
Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84
Chemoprevention of breast cancer. Expert Rev Anticancer Ther (2008) 0.84
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol (2010) 0.83
Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert Opin Ther Targets (2012) 0.83
Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol (2012) 0.83
Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells (2005) 0.82
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol (2014) 0.82
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat (2014) 0.81
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res (2014) 0.81
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol (2012) 0.81
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.81
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat (2010) 0.79
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med (2016) 0.78
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. Clin Colorectal Cancer (2007) 0.77
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol (2004) 0.77
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.77
Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77
Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep (2012) 0.77
Roles of cancer registries in enhancing oncology drug access in the Asia-Pacific region. Asian Pac J Cancer Prev (2013) 0.76
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer. JAMA (2005) 0.75
Rewarding innovation in drug discovery. Health Aff (Millwood) (2009) 0.75
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer. J Clin Oncol (2005) 0.75
Dipyrone-induced granulocytopenia: a case for awareness. Pharmacotherapy (2006) 0.75
Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers (2013) 0.75
Oncologic outcomes of neoadjuvant chemoradiation for locally advanced rectal cancer: a single-institution experience. Ann Acad Med Singapore (2014) 0.75
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer (2011) 0.75
Proposed clinical pathway for nonoperative management of high-grade pediatric pancreatic injuries based on a multicenter analysis: A pediatric trauma society collaborative. J Trauma Acute Care Surg (2017) 0.75
Proposed Clinical Pathway for Non-Operative Management of High-Grade Pediatric Pancreatic Injuries based on a Multicenter Analysis: A Pediatric Trauma Society Collaborative. J Trauma Acute Care Surg (2017) 0.75
Fulvestrant: clinical application of an estrogen receptor downregulator. Clin Ther (2002) 0.75
Introduction to special issue translational goals of neoadjuvant therapy. Breast Cancer Res Treat (2012) 0.75
Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Clin Adv Hematol Oncol (2008) 0.75
Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro. Stem Cells Dev (2004) 0.75